<p>The present invention relates to a ligand which specifically binds to the human tumor necrosis factor type 1 receptor (huTNFR1 ), the ligand comprising one or more amino acid sequences of human origin capable of reducing the immunogenic response of the ligand in human beings and one or more amino acid sequences capable of selectively binding to huTNFR1. The present invention further relates to a nucleic acid encoding said ligand and to a pharmaceutical composition for the treatment of disorders connected to huTNFR1.</p>
